Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024

Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% and liver triglycerides by 67% compared to placebo two months after administration Data also...

Related Keywords

Burlington ,Washington ,United States ,American ,Harith Rajagopalan ,Beth Brett ,Elisa Davidson ,American Gastroenterological Association ,Society For Surgery Of The Alimentary Tract ,Exchange Commission ,Nasdaq ,American Society For Gastrointestinal Endoscopy ,While The Company ,Corporate Communications ,Company Rejuva ,Stephen Jasper Gilmartin Group ,Fractyl Health ,Fractyl Health Inc ,Fractyl Health Rejuva ,Digestive Disease Week ,Chief Executive Officer ,Reduces Hepatic Triglycerides ,Murine Model ,About Fractyl ,American Association ,Liver Diseases ,American Society ,Gastrointestinal Endoscopy ,Alimentary Tract ,Private Securities Litigation Reform Act ,Quarterly Report ,Chief Financial Officer ,